单克隆丙种球蛋白病与ANCA相关性血管炎中的肾衰竭相关
本回顾性研究纳入167例ANCA相关性血管炎(AAV)伴肾脏受累且接受单克隆蛋白检测的患者,中位年龄68岁,50.8%为男性。调整基线蛋白尿、硬化性Berden分型和诱导治疗后,单克隆丙种球蛋白病(MG)与不良肾脏事件相关(HR 3.29,95%CI 1.12-9.68,P=.03)。基线MG与死亡率无关(HR 1.65,95%CI 0.87-3.12,P=.12),但6个月时持续MG的患者死亡率更高(HR 3.95,95%CI 1.10-14.21,P=.035)。
要点
- AAV伴肾脏受累患者中,MG与不良肾脏事件风险升高相关(HR 3.29)。
- 基线MG与死亡率无显著关联(HR 1.65,P=.12)。
- 6个月时持续MG者死亡率高于无MG或MG未持续者(HR 3.95,P=.035)。
核心结论
- 伴肾脏受累的AAV患者若存在MG,即使调整eGFR和慢性化程度等已知预测因素后,不良肾脏事件风险仍显著增加。
- MG导致不良结局的确切机制尚不清楚,需要进一步研究。
研究设计与样本
- 回顾性研究,纳入1999年11月至2023年12月间诊断为AAV伴肾脏受累且接受单克隆蛋白检测的患者。
- 肾脏生存分析共167例,分为单克隆阳性组(n=34)和单克隆阴性组(n=133)。
- 死亡率分析扩展队列至193例,额外纳入26例基线即依赖透析且随访期间持续透析的患者。
- 采用多因素Cox分析识别不良肾脏事件和死亡的预测因素。
主要发现
- 队列中位年龄68(58.5-74.5)岁,50.8%为男性,65.8% MPO阳性,64.6%接受利妥昔单抗诱导治疗。
- 调整基线蛋白尿、硬化性Berden分型和诱导治疗后,MG与不良肾脏事件相关(HR 3.29,95%CI 1.12-9.68,P=.03)。
- 基线MG与死亡率无关(HR 1.65,95%CI 0.87-3.12,P=.12)。
- 6个月时持续MG者死亡率高于无MG或MG未持续者(HR 3.95,95%CI 1.10-14.21,P=.035)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Up to 20% of patients with antineutrophil cytoplasmic antibody-associated vasculitis (AAV) and kidney involvement progress to end-stage kidney disease (ESKD) despite therapy. The role of monoclonal gammopathy (MG) in disease progression in patients with AAV is not well understood. METHODS: We conducted a retrospective study to identify patients diagnosed with AAV and renal involvement who had undergone monoclonal protein testing between November 1999 and December 2023. A total of 167 patients were included in the renal survival analysis and were categorized into monoclonal positive (n = 34) and monoclonal negative (n = 133) groups. For the mortality analysis, we expanded the cohort to include an additional 26 patients who were dialysis-dependent at baseline and remained on dialysis throughout follow-up, resulting in a total of 193 patients. We performed multivariate Cox analysis to identify predictors of adverse renal events [>40% decline in estimated glomerular filtration rate (eGFR) or ESKD (eGFR <15 mL/min/1.73 m², need for dialysis or transplantation)] and mortality. RESULTS: Median age of the cohort was 68 (58.5-74.5) years, with 50.8% males, 65.8% MPO positive, and 64.6% receiving rituximab as induction therapy. After adjusting for baseline proteinuria, sclerotic Berden class and induction therapy, MG was associated with adverse renal events [hazard ratio (HR) 3.29 (95% confidence interval 1.12-9.68), P = .03]. MG at baseline was not associated with mortality [HR 1.65 (0.87-3.12), P = .12], however patients with persistent MG at 6 months had higher mortality compared with those without MG or those whose MG was not sustained [HR 3.95 (1.10-14.21), P = .035]. CONCLUSIONS: Patients with AAV and renal involvement who have MG are at significantly increased risk of adverse renal events even after adjusting for factors such as eGFR and degree of chronicity (known predictors of poor renal outcome). The exact mechanism by which MG portends poor outcomes is poorly understood, and additional research is required.
引用
- Mekraksakit P, Vargas-Brochero MJ, Russo I, et al. Monoclonal gammopathy associates with kidney failure in ANCA-associated vasculitis. Nephrol Dial Transplant. 2026. PMID: 40982230. doi:10.1093/ndt/gfaf195
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。